Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12273714 | 0.94 | GRM2 (0.88) | GRM2GRM3 | |
| SCHEMBL11886412 | 0.91 | GRM2 (0.83) | GRM2GRM3 | |
| SCHEMBL232371 | 0.91 | GRM2 (0.83) | GRM2GRM3 | |
| Hydrochloric Acid SCHEMBL232370 | 0.90 | GRM2 (0.81) | GRM2GRM3 | |
| SCHEMBL30120557 | 0.89 | GRM2 (0.81) | GRM2GRM3 | |
| SCHEMBL4964584 | 0.89 | GRM2 (0.80) | GRM2GRM3 | |
| SCHEMBL5961906 | 0.89 | GRM2 (0.80) | GRM2GRM3 | |
| SCHEMBL7070920 | 0.89 | GRM2 (0.80) | GRM2GRM3 | |
| SCHEMBL231526 | 0.89 | GRM2 (0.80) | GRM2GRM3 | |
| SCHEMBL2002949 | 0.88 | GRM2 (0.79) | GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335430-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | UNIV YALE (US) | 2024-10-10 | — | — | US | claimed |
| US-20240240152-A1 | Protection of Beta Cells from Immune Attack | JOSLIN DIABETES CENTER (US) | 2024-07-18 | — | — | US | claimed |
| US-20240033254-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | UNIV YALE (US) | 2024-02-01 | — | — | US | claimed |
| CN-116267014-A | Cyclic deuterated gaboxadol and its use for treating psychotic disorders | CERTEGO治疗公司 | 2023-06-20 | — | — | CN | claimed |
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2023-06-15 | — | — | US | claimed |
| EP-4153549-A2 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Certego Therapeutics Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | Certego Therapeutics Inc. (US) | 2023-03-07 | — | — | US | claimed |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2022-04-28 | — | — | US | claimed |
| US-20210251969-A1 | Combination Therapy for Treating or Preventing Depression or Other Mood Diseases | YALE UNIVERSITY | 2021-08-19 | — | — | US | claimed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260125651-A1 | Protection of Beta Cells from Immune Attack | JOSLIN DIABETES CENTER (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260098030-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | UNIV VANDERBILT (US) | 2026-04-09 | — | — | US | disclosed |
| US-12545895-B2 | Protection of beta cells from immune attack | JOSLIN DIABETES CENTER (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4673136-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | Vanderbilt University (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20070021394-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070021394-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7157594-B2 | 6-Fluorobicyclo[3.1.0]hexane derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1637517-A1 | 2-AMINOBICYCLO 3.1.0 HEXANE-2,6-DICARBOXYLIC ESTER DERIVATIVE | Taisho Pharmaceutical Co. Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050119345-A1 | 6-Fluorobicyclo[3.1.0]hexane derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| CN-1610557-A | 6-fluorobicyclo [3.1.0] hexane derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2005-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119345-A1 | 6-Fluorobicyclo[3.1.0]hexane derivatives | GRM1, GRM2, GRM6 | GRM2 2/4885GRM3 4/4885 |
| US-20260098030-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM2, GRM1, GRIN2C | GRM2 1/4885GRM3 5/4885 |
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | GRM2 53/4885GRM3 29/4885 |
| US-20070021394-A1 | 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative | GRIN2C, GRIK4, GRIN2B | GRM2 13/4885GRM3 10/4885 |
| US-20260125651-A1 | Protection of Beta Cells from Immune Attack | IAPP, SPPL2B, TXNL1 | GRM2 4721/4885GRM3 4636/4885 |
| US-12545895-B2 | Protection of beta cells from immune attack | PLIN1, GLS, GCKR | GRM2 8/4885GRM3 32/4885 |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | GRM2 53/4885GRM3 29/4885 |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | GABRD, GABRA6, GABRA3 | GRM2 53/4885GRM3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.